Multiple myeloma (MM), a blood cancer disease, is rarely curable despite major advances in therapy. Clinical experience shows that monoclonal antibodies (mAbs) can be effective in MM, especially when combined with today's standard therapies. However, the currently clinically used mAbs are all directed against surface structures that are also found on healthy tissue.

In the context of this project, a cellular screening system is being developed, which uses the so-called phage display and tumor cells of MM patients to search for new mAbs directed against myeloma-specific surface structures. Extensive sequence analyses should additionally support the identification of new, specific mAbs against myeloma cells.

Here you can get further information.